Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2008-07-01
Series:	PLoS Genetics
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2648616/?tool=EBI

Similar Items

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53.
by: Jennifer J. Jordan, et al.
Published: (2008-07-01)

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53
Published: (2008-10-01)

Correction: Noncanonical DNA Motifs as Transactivation Targets by Wild Type and Mutant p53.
by: Jennifer J. Jordan, et al.
Published: (2008-10-01)

Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.
by: Jennifer J Jordan, et al.
Published: (2008-06-01)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
by: Shengliang Zhang, et al.
Published: (2022-04-01)

Regression based predictor for p53 transactivation
by: Gowrisankar Sivakumar, et al.
Published: (2009-07-01)

DNA methylation modifier LSH inhibits p53 ubiquitination and transactivates p53 to promote lipid metabolism
by: Ling Chen, et al.
Published: (2019-10-01)

Thermodynamic stability of wild-type and mutant p53 core domain.
by: Bullock, A, et al.
Published: (1997)

Editorial: Advances in wild type and mutant p53 research in cancer
by: Olga N. Hernández-de la Cruz, et al.
Published: (2022-11-01)

The MDM2-binding region in the transactivation domain of p53 also acts as a Bcl-XL-binding motif
by: Xu, Huibin, et al.
Published: (2012)

Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
by: Phong Lu, et al.
Published: (2019-05-01)

Mutant and Wild-Type Tumor Suppressor p53 Induces p300 Autoacetylation
by: Stephanie Kaypee, et al.
Published: (2018-06-01)

p32 is a negative regulator of p53 tetramerization and transactivation
by: Nikhil Baban Ghate, et al.
Published: (2019-09-01)

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis
by: Hiraki, Masatsugu, et al.
Published: (2017)

The inhibition of autophagy sensitises colon cancer cells with wild-type p53 but not mutant p53 to topotecan treatment.
by: Dan-Dan Li, et al.
Published: (2012-01-01)

Recent findings on the role of wild-type and mutant p53 in cancer development and therapy
by: Mehregan Babamohamadi, et al.
Published: (2022-09-01)

Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition
by: Oleg Semenov, et al.
Published: (2022-06-01)

Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant.
by: Khaled Barakat, et al.
Published: (2011-01-01)

Mutant p53 cooperates with knockdown of endogenous wild-type p53 to disrupt tubulogenesis in Madin-Darby canine kidney cells.
by: Yanhong Zhang, et al.
Published: (2013-01-01)

Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties
by: Mizuho Nakayama, et al.
Published: (2020-05-01)

A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis
by: Margaret A. Ferris, et al.
Published: (2022-02-01)

Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
by: Elena Butturini, et al.
Published: (2021-11-01)

Wild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management?
by: Marco Corazzari, et al.
Published: (2023-03-01)

The Competition of Yin and Yang: Exploring the Role of Wild-Type and Mutant p53 in Tumor Progression
by: Bi-He Cai, et al.
Published: (2023-04-01)

NPC-Exosome Carry Wild and Mutant-type p53 among Nasopharyngeal Cancer Patients
by: Hamsu Kadriyan, et al.
Published: (2021-12-01)

Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen
by: Lionel Low, et al.
Published: (2019-11-01)

Inhibitory member of the apoptosis-stimulating proteins of the p53 family (iASPP) interacts with protein phosphatase 1 via a noncanonical binding motif.
by: Llanos, S, et al.
Published: (2011)

The 9aaTAD Transactivation Domains: From Gal4 to p53.
by: Martin Piskacek, et al.
Published: (2016-01-01)

Differences in the transactivation domains of p53 family members: a computational study
by: Beuerman Roger W, et al.
Published: (2010-02-01)

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability
by: YiQing Lü, et al.
Published: (2024-04-01)

Anticancer efficacy of hirsuteine against colorectal cancer by opposite modulation of wild-type and mutant p53
by: Yan Zhang, et al.
Published: (2023-05-01)

Targeting mutant p53 stabilization for cancer therapy
by: Jiajian Wang, et al.
Published: (2023-07-01)

Targeting mutant p53 in cancer: the latest insights
by: Silvia Di Agostino, et al.
Published: (2019-07-01)

Mutant p53 as a Regulator and Target of Autophagy
by: Yong Shi, et al.
Published: (2021-02-01)

Mutant p53 in Cancer Progression and Targeted Therapies
by: Gaoyang Zhu, et al.
Published: (2020-11-01)

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
by: Li Ren Kong, et al.
Published: (2020-04-01)

Che-1/AATF: a critical co-factor for both wild type- and mutant-p53 proteins
by: Tiziana eBruno, et al.
Published: (2016-02-01)

Structural Basis for the Interaction between p53 Transactivation Domain and the Mediator Subunit MED25
by: Min-Sung Lee, et al.
Published: (2018-10-01)

p53’s Extended Reach: The Mutant p53 Secretome
by: Evangelos Pavlakis, et al.
Published: (2020-02-01)

Stability and Existence of Noncanonical I-motif DNA Structures in Computer Simulations Based on Atomistic and Coarse-Grained Force Fields
by: Tomasz Panczyk, et al.
Published: (2022-08-01)